These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21510895)

  • 61. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder.
    Bukstein OG; Kolko DJ
    J Clin Child Psychol; 1998 Oct; 27(3):340-51. PubMed ID: 9789193
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of methylphenidate on the cognitive and personality functioning of ADHD children.
    Lufi D; Parish-Plass J; Gai E
    Isr J Psychiatry Relat Sci; 1997; 34(3):200-9. PubMed ID: 9334525
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pre-Existing Comorbid Emotional Symptoms Moderate Short-Term Methylphenidate Adverse Effects in a Randomized Trial of Children with Attention-Deficit/Hyperactivity Disorder.
    Froehlich TE; Brinkman WB; Peugh JL; Piedra AN; Vitucci DJ; Epstein JN
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):137-147. PubMed ID: 31841646
    [No Abstract]   [Full Text] [Related]  

  • 65. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.
    Gruber R; Joober R; Grizenko N; Leventhal BL; Cook EH; Stein MA
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):233-9. PubMed ID: 19519258
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
    Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
    J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
    Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
    Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
    Gorman EB; Klorman R; Thatcher JE; Borgstedt AD
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):808-16. PubMed ID: 16832317
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
    Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
    Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
    Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
    J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
    [No Abstract]   [Full Text] [Related]  

  • 74. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
    Rösler M; Ginsberg Y; Arngrim T; Adamou M; Niemelä A; Dejonkheere J; van Oene J; Schäuble B
    World J Biol Psychiatry; 2013 May; 14(4):282-90. PubMed ID: 21517701
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD.
    Pearson DA; Santos CW; Roache JD; Casat CD; Loveland KA; Lachar D; Lane DM; Faria LP; Cleveland LA
    J Am Acad Child Adolesc Psychiatry; 2003 Feb; 42(2):209-16. PubMed ID: 12544181
    [TBL] [Abstract][Full Text] [Related]  

  • 77. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
    Wigal SB; Childress AC; Belden HW; Berry SA
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):3-10. PubMed ID: 23289899
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effectiveness of methylphenidate in Native American children with fetal alcohol syndrome and attention deficit/hyperactivity disorder: a controlled pilot study.
    Oesterheld JR; Kofoed L; Tervo R; Fogas B; Wilson A; Fiechtner H
    J Child Adolesc Psychopharmacol; 1998; 8(1):39-48. PubMed ID: 9639078
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A randomized, rater-blinded, crossover study comparing the clinical efficacy of Ritalin(®) LA (methylphenidate) treatment in children with attention-deficit hyperactivity disorder under different breakfast conditions over 2 weeks.
    Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Haessler F; Linder M; Stollhoff K; Warnke A; Baier M; Klatt J
    Atten Defic Hyperact Disord; 2010 Nov; 2(3):133-8. PubMed ID: 21432599
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder.
    Turner DC; Blackwell AD; Dowson JH; McLean A; Sahakian BJ
    Psychopharmacology (Berl); 2005 Mar; 178(2-3):286-95. PubMed ID: 15338103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.